RYRabi Yacoub

Rabi Yacoub

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rabi Yacoub has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Mark A. Bryniarski

    Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 303 Pharmacy Building, Buffalo, NY, 14214, USA

    4 shared publications
  • Lee D. Chaves

    Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, 875 Ellicott St, Buffalo, NY, 14214, USA

    3 shared publications
  • Sham Abyad

    Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, USA

    3 shared publications
  • Amanda M. Honan

    Department of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo , Buffalo, New York

    2 shared publications
  • Corrine M. Stahura

    Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University—SUNY, Binghamton, NY 13790, USA

    2 shared publications
  • Jaime Uribarri

    Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

    2 shared publications

Latest Publications

  • Open Access

    Unconjugated p-cresol activates macrophage macropinocytosis leading to increased LDL uptake

    by Lee D. Chaves, Sham Abyad, Amanda M. Honan, Mark A. Bryniarski, Daniel I. McSkimming, Corrine M. Stahura, Steven C. Wells, Donna M. Ruszaj, Marilyn E. Morris, Richard J. Quigg, et al.

    Patients with chronic kidney disease (CKD) and end-stage renal disease suffer from increased cardiovascular events and cardiac mortality. Prior studies have demonstrated that a portion of this enhanced risk can be attributed to the accumulation of microbiota-derived toxic metabolites, with most studies focusing on the sulfonated form of p -cresol (PCS). However, unconjugated p- cresol (uPC) itself was never assessed due to rapid and extensive first-pass metabolism that results in negligible serum concentrations of uPC. These reports thus failed to consider the host exposure to uPC prior to hepatic metabolism. In the current study, not only did we measure the effect of altering the intestinal microbiota on lipid accumulation in coronary arteries, but we also examined macrophage lipid uptake and handling pathways in response to uPC. We found that atherosclerosis-prone mice fed a high-fat diet exhibited significantly higher coronary artery lipid deposits upon receiving fecal material from CKD mice. Furthermore, treatment with uPC increased total cholesterol, triglycerides, and hepatic and aortic fatty deposits in non-CKD mice. Studies employing an in vitro macrophage model demonstrated that uPC exposure increased apoptosis whereas PCS did not. Additionally, uPC exhibited higher potency than PCS to stimulate LDL uptake and only uPC induced endocytosis- and pinocytosis-related genes. Pharmacological inhibition of varying cholesterol influx and efflux systems indicated that uPC increased macrophage LDL uptake by activating macropinocytosis. Overall, these findings indicate that uPC itself had a distinct effect on macrophage biology that might have contributed to increased cardiovascular risk in patients with CKD.


  • Megalin-mediated albumin endocytosis in cultured murine mesangial cells

    by Mark A. Bryniarski, Benjamin M. Yee, Lee D. Chaves, Corrine M. Stahura, Rabi Yacoub, Marilyn E. Morris


  • The Gastrointestinal Microbiome in Chronic Renal Diseases

    by Mark A. Bryniarski, Sarah E. M. Hoffman, Rabi Yacoub

  • The role of chronic kidney disease-associated dysbiosis in cardiovascular disease

    by Mark A Bryniarski, Fares Hamarneh, Rabi Yacoub

    Survival outcomes of patients with end stage renal disease are worse than those of many metastatic cancers. Kidney disease patients are often inflicted with higher rates of cardiovascular disease, in which nearly half of the mortalities are attributed to adverse cardiovascular events. Of the multifarious reasons for this detrimental impact, dysbiosis in the intestinal microbiome is surfacing as a potential participant. This is likely due to the numerous metabolic and inflammatory shifts found in chronic kidney disease, as well as environmental changes within the intestinal lumen. Studies are beginning to link microbiota alterations mediated by chronic kidney disease to negative cardiovascular outcomes. Here, recent findings connecting dysbiosis in chronic kidney disease and various cardiovascular insults are reviewed.Impact statement: Negative alterations, or dysbiosis, in the intestinal microbial community balance in response to chronic kidney disease is emerging as a substantial and important factor in inducing and exacerbating multiple comorbid conditions. Patients with renal insufficiency experience a substantial increase in cardiovascular risk, and recent evidence is shedding light on the close interaction between microbiome dysbiosis and increased cardiovascular events in this population. Previous association and recent causality studies utilizing experimental animal models have enriched our understanding and confirmed the impact of microbial community imbalance on cardiac health in both the general population and in patients with renal impairment.


  • Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study

    by Rabi Yacoub, Girish N Nadkarni, Daniel I McSkimming, Lee D Chaves, Sham Abyad, Mark A Bryniarski, Amanda M Honan, Shruthi A Thomas, Madan Gowda, John C He, et al.

    Gut bacterial microbiota is altered in patients with advanced renal disease and those on dialysis. However, it is not clear yet what bacterial composition changes are due to the renal insufficiency per se, and what are in result of the accompanying interventions and comorbid conditions. Most studies analyzed diabetic nephropathy, hypertensive nephropathy, and glomerulonephritis patients which might have directly influenced the microbiome regardless of alterations in renal function. We present in this report changes in gut bacterial microbiota in a highly selected group of patients with strict inclusion criteria to eliminate the effects of the confounding factors on the microbiome composition. We conducted multiple analysis approaches according to participants’ renal function to further understand microbiome alteration in different degrees of renal insufficiency. An interesting group of bacteria showed a step-wise change in relative abundance in response to the three groups’ analysis. These bacteria either decreased or increased from mild, moderate to severe renal insufficiency indicating strong and direct effects of the uremic milieu on its relative abundance. We also ran a sensitivity analysis that took into account an assembly of the significant taxa observed in an approach to investigate whether these taxa can fully explain the separation noted between the groups. We determined the projected metabolic pathways altered according to the gut microbiota composition changes. This report not only delineates with a higher certainty the effects of alteration in renal function on the microbiome, but also explores the possible role of dysbiosis on comorbid conditions through alterations in the projected metabolic pathways.Impact statement: The heterogeneity of the renal disease, therapeutic interventions, and the original cause of the renal failure, all directly affect the microbiota. We delineate in this report the direct effect of decreased renal function on the bacterial composition following stringent criteria to eliminate the possibilities of other confounding factors and dissect the direct effects of the uremic milieu. We analyzed the microbiome following three different approaches to further evaluate the effects of mild, moderate and advanced renal insufficiency on the microbiome. We also present here a detailed functional analysis of the projected altered pathways secondary to changes in the microbiome composition.


  • Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis

    by Lee D. Chaves, Daniel I. McSkimming, Mark A. Bryniarski, Amanda M. Honan, Sham Abyad, Shruthi A. Thomas, Steven Wells, Michael J Buck, Yijun Sun, Robert J. Genco, et al.

    Several lines of evidence suggest that gut bacterial microbiota is altered in patients with chronic kidney disease (CKD), though the mechanism of which this dysbiosis takes place is not well understood. Recent studies delineated changes in gut microbiota in both CKD patients and experimental animal models using microarray chips. We present 16S ribosomal RNA gene sequencing of both stool pellets and small bowel contents of C57BL/6J mice that underwent a remnant kidney model and establish that changes in microbiota take place in the early gastrointestinal tract. Increased intestinal urea concentration has been hypothesized as a leading contributor to dysbiotic changes in CKD. We show that urea transporters (UT)-A and UT-B mRNA are both expressed throughout the whole gastrointestinal tract. The noted increase in intestinal urea concentration appears to be independent of UTs’ expression. Urea supplementation in drinking water resulted in alteration in bacterial gut microbiota that is quite different than that seen in CKD. This indicates that increased intestinal urea concentration might not fully explain the CKD- associated dysbiosis.


  • Open Access

    Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial

    by Rabi Yacoub, Melinda Nugent, Weijin Cai, Girish N. Nadkarni, Lee D. Chaves, Sham Abyad, Amanda M. Honan, Shruthi A. Thomas, Wei Zheng, Sujith A. Valiyaparambil, et al.

    The modern Western diet is rich in advanced glycation end products (AGEs). We have previously shown an association between dietary AGEs and markers of inflammation and oxidative stress in a population of end stage renal disease (ESRD) patients undergoing peritoneal dialysis (PD). In the current pilot study we explored the effects of dietary AGEs on the gut bacterial microbiota composition in similar patients. AGEs play an important role in the development and progression of cardiovascular (CVD) disease. Plasma concentrations of different bacterial products have been shown to predict the risk of incident major adverse CVD events independently of traditional CVD risk factors, and experimental animal models indicates a possible role AGEs might have on the gut microbiota population. In this pilot randomized open label controlled trial, twenty PD patients habitually consuming a high AGE diet were recruited and randomized into either continuing the same diet (HAGE, n = 10) or a one-month dietary AGE restriction (LAGE, n = 10). Blood and stool samples were collected at baseline and after intervention. Variable regions V3-V4 of 16s rDNA were sequenced and taxa was identified on the phyla, genus, and species levels. Dietary AGE restriction resulted in a significant decrease in serum Nε-(carboxymethyl) lysine (CML) and methylglyoxal-derivatives (MG). At baseline, our total cohort exhibited a lower relative abundance of Bacteroides and Alistipes genus and a higher abundance of Prevotella genus when compared to the published data of healthy population. Dietary AGE restriction altered the bacterial gut microbiota with a significant reduction in Prevotella copri and Bifidobacterium animalis relative abundance and increased Alistipes indistinctus, Clostridium citroniae, Clostridium hathewayi, and Ruminococcus gauvreauii relative abundance. We show in this pilot study significant microbiota differences in peritoneal dialysis patients’ population, as well as the effects of dietary AGEs on gut microbiota, which might play a role in the increased cardiovascular events in this population and warrants further studies.


  • Open Access

    Association between probiotic and yogurt consumption and kidney disease: insights from NHANES

    by Rabi Yacoub, Deepak Kaji, Shanti N. Patel, Priya K. Simoes, Deepthi Busayavalasa, Girish N. Nadkarni, John C. He, Steven G. Coca, Jaime Uribarri

    Data from experimental animals suggest that probiotic supplements may retard CKD progression. However, the relationship between probiotic use, frequent yogurt consumption (as a natural probiotic source), and kidney parameters have not been evaluated in humans. We utilized NHANES data, and analyzed the association of probiotic alone (1999–2012) and yogurt/probiotic (2003–2006) use with albuminuria and eGFR after adjustment for demographic and clinical parameters. Frequent yogurt consumption was defined as thrice or more weekly over the year prior to the interview. Frequent yogurt/probiotic consumers had lower adjusted odds of developing combined outcome (albuminuria and/or eGFR < 60 ml/min/1.73 m2) compared to infrequent consumers (OR = 0.76; 95 % CI = 0.61-0.94). When evaluated separately, frequent consumers had lower odds of albuminuria and nonsignificant trend towards decreased odds of low eGFR compared to infrequent consumers. In the probiotic cohort, probiotic consumers were found to have a lower adjusted odds of albuminuria compared to nonusers (OR = 0.59; 95 % CI = 0.37–0.94). Frequent yogurt and/or probiotics use is associated with decreased odds of proteinuric kidney disease. These hypothesis-generating results warrant further translational studies to further delineate the relationship between yogurt/probiotics with kidney dysfunction, as well as microbiome and dysbiosis as potential mediators.


  • Open Access

    Urinary Tract Infections and Asymptomatic Bacteriuria in Renal Transplant Recipients

    by Rabi Yacoub, Nader Kassis Akl

    Asymptomatic bacteriuria and urinary tract infection are common complications after kidney transplantation. In this population, if urinary tract infection occurred in the first six months post procedure, it carries a grave impact on both graft and patient survival. Renal transplant recipients with urinary tract infection are often clinically asymptomatic as a consequence of immunosuppression. Urinary tract infection, however, may progress to acute pyelonephritis, bacteremia and the full blown picture of urosepsis. PubMed and Cochrane databases were searched. The purpose of this review is to discuss the screening and treatment of urinary tract infection and asymptomatic bacteriuria in renal transplant recipients and to evaluate the guidelines on the basis of a review of published evidence.